Abstract 69P
Background
Colorectal cancer is one of the commonest malignancies worldwide. Next Generation Sequencing (NGS) helps inform treatment pathways for patients post surgery, and also provides valuable information regarding genetic mutations in cancer, the pathogenesis and biology of the disease. We reviewed NGS mutation profiling in our colorectal cancer patients.
Methods
NGS analysis was performed over a 7 year period. Data retrieved from medical records and pathology reports.
Results
92 patients underwent surgery for colorectal cancer during the study period. Mean age: 71 years (Range:44-87). M:F: 1.05:1 43 patients (46.7%) were found to have mutations on NGS sequencing. No significant difference in age, sex, tumour size, lymph node ratio or stage at presentation between the two groups. NGS mutation was significantly associated with right sided disease (p=0.01, Fishers exact test), and this association was highly significant for the BRAF V600e mutation (p=0.0001), NGS mutation was significantly associated with mucinous disease (p=0.04), lymphovascular and / or perineural invasion (p=0.02), and microsatellite instability (p=0.0136), but not metastatic disease at presentation (p=1). Kaplan Meier survival analysis revealed no difference in survival between patients with NGS mutations and those without (p=0.52) or on any subset analysis. COX proportional hazards testing revealed only a significant relationship between tumour size and survival in all patients on multivariate analysis (p=0.002).
Conclusions
NGS sequencing provides relevant information regarding the association of cancers with aggressive features and microsatellite instability. Association of the BRAF mutation with right sided colon cancers has been described previously and may reflect a different pathway to carcinogenesis in the right colon, which has been postulated to have a different origin to the left colon. Significant association of gene mutations with microsatellite instability, but no difference in metastatic disease and overall survival may relect better immune response to these tumours, MSI has been observed to be associated with reduced risk of metastasis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
121P - DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution
Presenter: Nnenna Kanu
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Comprehensive multi-omics profiling identifies prognostic and predictive subtypes in renal cell carcinoma
Presenter: Sanha Park
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Copy number from ulcWGS to predict TNBC molecular subtypes in the IBCSG 22-00 trial
Presenter: Andrea Joaquin Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
124P - Targeting neoantigens in chronic lymphocytic leukemia (CLL) for personalized T cell therapy
Presenter: Gurvinder Kaur
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Detection and analysis of medulloblastoma subtype-specific copy number variations from RNA-seq data for improved risk-based subtype classification
Presenter: Ivan Martinez de Estibariz Royuela
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Genomic and transcriptomic profiles define smokers and non-smokers lung squamous cell carcinoma patients
Presenter: Matteo Canale
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Metastatic migrations in lung cancer: Insights from the PEACE autopsy programme
Presenter: Sonya Hessey
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - NGS prescreening program for refractory solid tumors outside standard indications in a public network of cancer centers
Presenter: Paula Sàbat Viltró
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Transcriptomic analysis of patients with metastatic hormone-sensitive prostate cancer to identify genomic signatures involved in the transition from androgen-dependent to androgen-independent phenotype
Presenter: Giovanna Pecoraro
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Benchmarking whole exome sequencing in the German network for personalized medicine
Presenter: Michael Menzel
Session: Cocktail & Poster Display session
Resources:
Abstract